A
Ana M. Gonzalez-Angulo
Researcher at University of Texas Health Science Center at Houston
Publications - 12
Citations - 5292
Ana M. Gonzalez-Angulo is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 11, co-authored 12 publications receiving 4557 citations. Previous affiliations of Ana M. Gonzalez-Angulo include University of Münster & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke,Chafika Mazouni,Kenneth R. Hess,Fabrice Andre,Attila Tordai,Jaime A. Mejia,W. Fraser Symmans,Ana M. Gonzalez-Angulo,Bryan T. Hennessy,Marjorie C. Green,Massimo Cristofanilli,Gabriel N. Hortobagyi,Lajos Pusztai +12 more
TL;DR: Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival, however, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with other patients, particularly in the first 3 years.
Journal ArticleDOI
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf,Anne V. Philips,Funda Meric-Bernstam,Na Qiao,Yun Wu,Susan M. Harrington,Xiaoping Su,Ying Wang,Ana M. Gonzalez-Angulo,Argun Akcakanat,Akhil Chawla,Michael Curran,Patrick Hwu,Padmanee Sharma,Jennifer K. Litton,Jeffrey J. Molldrem,Gheath Alatrash +16 more
TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.
Journal ArticleDOI
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
Valentina Guarneri,Kristine Broglio,Shu Wan Kau,Massimo Cristofanilli,Aman U. Buzdar,Vicente Valero,Thomas A. Buchholz,Funda Meric,Lavinia P. Middleton,Gabriel N. Hortobagyi,Ana M. Gonzalez-Angulo +10 more
TL;DR: In this paper, the authors evaluated whether hormonal receptor status can influence the prognostic significance of pathologic complete response (pCR) in stage I to III non-invasive breast cancer.
Journal ArticleDOI
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Ana M. Gonzalez-Angulo,Jennifer K. Litton,Kristine Broglio,Funda Meric-Bernstam,Ronjay Rakkhit,Fatima Cardoso,Florentia Peintinger,Emer O Hanrahan,Aysegul A. Sahin,Merih Guray,D. Larsimont,Francesco Feoli,Heidi Stranzl,Thomas A. Buchholz,Vicente Valero,Richard L. Theriault,Martine Piccart-Gebhart,Peter M. Ravdin,Donald A Berry,Gabriel N. Hortobagyi +19 more
TL;DR: Patients with HER2-positive T1abN0M0 tumors have a significant risk of relapse and should be considered for systemic, anti-HER2, adjuvant therapy.
Journal ArticleDOI
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer
Todd W. Miller,Justin M. Balko,Emily M. Fox,Zara Ghazoui,Anita K. Dunbier,Helen Anderson,Mitchell Dowsett,Aixiang Jiang,R. Adam Smith,Sauveur-Michel Maira,H. Charles Manning,Ana M. Gonzalez-Angulo,Gordon B. Mills,Catherine F. Higham,Siprachanh Chanthaphaychith,Maria G. Kuba,William R. Miller,Yu Shyr,Carlos L. Arteaga +18 more
TL;DR: The identified an estrogen-independent role for ER and the CDK4/Rb/E2F transcriptional axis in the hormone-independent growth of breast cancer cells and their combination with PI3K inhibitors for treatment of antiestrogen-resistant breast cancers.